Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.5.4.4 (
adenosine deaminase
)
5,136
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Fludarabine phosphate is a synthetic analog of beta-arabinofuranosyl adenine (beta-ara-A), an anti-viral agent. Since beta-ara-A has been shown to be an effective inhibitor of potentially lethal damage (PLD) repair in cell culture system but ineffective in in vivo tumors, we carried out experiments to determine whether fludarabine phosphate which is not inactivated by
adenosine deaminase
potentiates the radiation effects on in vivo murine
tumor
. The combined effects of single acute fludarabine phosphate (600 mg/kg) and single dose of X-irradiation (20 Gy) on Meth-A fibrosarcomas in BALB/c mice produced more than 90%
tumor
control, while the radiation alone resulted in less than 10%
tumor
control. The radiosensitizing effect by fludarabine phosphate was higher when the drug was administered immediately prior to X-irradiation. The dose modifying factor of fludarabine phosphate is estimated to be 1.6 at 400 mg/kg. Experiments with fractionated irradiation and fludarabine phosphate similarly showed a high rate of
tumor
control. The present study suggests that inhibitors of PLD repair including several antiviral agents may have potential utility in the treatment of some radioresistant human tumors by radiotherapy.
...
PMID:The potentiation of radiation response on murine tumor by fludarabine phosphate. 242 70
In C57BL/6 mice, cytotoxic T lymphocyte (CTL) lines have previously been found to exhibit low (less than 150 U/mg) or undetectable (less than 20 U/mg)
adenosine deaminase
(
ADA
) levels (Minkowski, Castellazzi and Buttin, J. Immunol. 1984. 133: 52) in contrast to what has been seen in T helper lines (1770 +/- 340 U/mg; Minkowski and Bandeira, Cell. Immunol. 1985. 95: 380). Treatment of one of these CTL
ADA
- lines with the demethylating agent 5-azacytidine gave rise to an ADA+ population. Subsequent cloning allowed the recovery of pure ADA+ clones showing a rather narrow range of activity with an average value of 2030 +/- 504 U/mg. The restored ADA+ activity is stable over several months of continuous growth. It is identical to the activity of C57BL/6 thymic cells or C57BL/6 T
tumor
lines regarding its sensitivity to
ADA
inhibitors 2-deoxycoformycin and erythro-9-(2-hydroxyl-3-nonyl)adenine, and its electrophoretic mobility under nondenaturing conditions (starch gel and isoelectric focusing). An
ADA
-specific, 1.4-kb mRNA is present in the reactivated clones but is undetectable in the CTL
ADA
- parental line. These results demonstrate that the
ADA
- phenotype is due to an extinction of the corresponding gene. They suggest that the extinction of the
ADA
gene which appears to be specific for CTL and to take place in vivo during T cell differentiation may result from increased methylation in or near the
ADA
gene. This extinction seems to affect specifically
ADA
since nucleoside phosphorylase, the enzyme which follows
ADA
in the purine salvage pathway, is present at equivalent levels in the
ADA
- and ADA+ CTL clones.
...
PMID:Azacytidine-induced reactivation of adenosine deaminase in a murine cytotoxic T cell line. 242 25
Hairy cell leukemia (HCL) is a rare chronic lymphoproliferative disorder which has been extensively studied over the past decade. Much has been learned regarding the diagnosis, natural history, biology, and treatment of this unique
neoplasm
. The disease most commonly affects middle aged men and characteristic clinical features include splenomegaly, cytopenias, and usually the presence in the peripheral blood of distinctive 'hairy cells' with irregular cytoplasmic projections. Diagnosis can usually be confirmed by bone marrow biopsy. Although the natural history can be extremely variable among patients, complications are usually referable to the cytopenias, with anemia and infection being most frequent. In addition to pyogenic infections, patients are susceptible to unusual organisms including atypical mycobacterium, legionella, and fungi. The requirement of red blood cell transfusion, severe granulocytopenia or thrombocytopenia, frequent infections, or painful splenomegaly are all indications for treatment. Splenectomy is the standard initial treatment of choice. However, in the past few years there have been exciting major advances in the therapeutic modalities for HCL. Recombinant alpha-interferon is highly effective, with beneficial responses occurring in close to 90% of patients. The Food and Drug Administration has recently approved the use of interferon for HCL. This represents the first time a biological response modifier has been approved for the treatment of human disease. In addition, preliminary results with the
adenosine deaminase
inhibitor, 2'deoxycoformycin (dcf), have been encouraging. Further clinical trials are required in order to determine the optimal sequential treatment strategy for HCL. The exact mechanisms of action of both interferon and dcf in HCL remain to be elucidated. A better understanding of the unusual features of the hairy cell and the underlying biological effect of these two agents in HCL may have important applications in other hematologic and non-hematologic malignancies.
...
PMID:Hairy cell leukemia: clinical features and therapeutic advances. 244 91
Fludarabine (9-beta-D-arabinofuranosyl 2-fluoro-adenine monophosphate) is a fluorinated analogue of adenine which is relatively resistant to deamination by
adenosine deaminase
. Phase I clinical trials disclosed significant antitumor activity in lymphoid malignancies. Fludarabine has been used in the treatment of CLL since March, 1985, at a dose of 25-30 mg/m2/day x 5 days each 3-4 weeks by short intravenous infusion. Sixty-eight previously treated patients with CLL are evaluable for response. The median age was 60 years, 50 were male the median number of prior chemotherapy regimens was 2, and the median time from initial chemotherapy to fludarabine was 45 months. Forty-three (63%) were Rai stages 3 and 4, 31 (46%) were Binet Stage C. Twenty patients (29%) obtained a complete remission (CR), defined as peripheral lymphocytes less than 4,000/microliters, no clinical evidence of disease, less than 30% of lymphocytes in the bone marrow (with no residual nodules), or a nodular partial remission, NPR (CR except for residual lymphoid nodules), and 19 (28%) a partial remission (less than 50% reduction in
tumor
in nodes, liver, spleen and bone marrow and greater than 1 log reduction in the lymphocyte count). The complete remission rate for the various involved sites were blood (69%), liver (52%), spleen (55%), and nodes (48%). The bone marrow was the least responsive site with 16% CR and 44% PR. The number of prior regimens did not have a significant response rate or survival. The serum albumin , alkaline phosphatase, platelet and hemoglobin level all were associated with survival from the start of fludarabine.(ABSTRACT TRUNCATED AT 250 WORDS)
...
PMID:Fludarabine therapy in chronic lymphocytic leukemia (CLL). 246 94
The value of seric activity of
adenosine deaminase
has been detected in four group of patients with liver disease: acute viral hepatitis in 32 cases, liver cirrhosis in 30 cases, liver
neoplasia
in 12 cases, and cholelithiasis in 20 cases, against 30 patients as a control group. In addition, we studied 3 patients with alcoholic hepatitis and 1 with biliary cirrhosis. The highest level was found in hepatic cirrhosis and viral hepatitis the value being statistically significant and superior to the levels of the control group in 100% of the cases. This level was higher than normal in patients with liver
tumor
. The level was normal or mildly elevated in patients with cholelithiasis. The level was normal in patients with alcoholic hepatitis and high in biliary cirrhosis but lower than that observed in alcoholic cirrhosis.
...
PMID:[Enzymatic activity of serum adenosine deaminase in different liver disorders]. 249 53
The subject of this investigation was an 11-month-old infant girl who presented with a pathological fracture of the right femur due to a metastasis from an abdominal immunoblastic sarcoma. Her past history included recurrent, intractable bacterial and fungal infections. Investigations of her immune status revealed low numbers of T-lymphocytes, a reversed T-helper (TH)/T-suppressor (TS) cell ratio, no response of her peripheral blood lymphocytes to pokeweed mitogen, phytohemagglutinin, concanavalin A, and Candida albicans, and an inability of her cells to react in a mixed lymphocyte culture. Serum levels of IgG, IgM, and IgA were all below normal. No thymic shadow was visible on the chest radiograph. There was no evidence of
adenosine deaminase
or nucleoside phosphorylase deficiencies. The
tumor
cells exhibited both surface IgM and IgG, and many of the cells contained large amounts of cytoplasmic IgM. Light chain specificity was restricted to lambda chain for both surface and cytoplasmic immunoglobulin. Ultrastructural study of the
tumor
cells revealed the presence of both intranuclear and cytoplasmic virions in roughly 1% of the
tumor
cells. These viral particles strongly resembled herpes viruses. DNA-hybridization studies on the
neoplasm
revealed the presence of 7-10 genome equivalents of Epstein-Barr virus-DNA per
tumor
cell.
...
PMID:Demonstration of Epstein-Barr virus in immunoblastic sarcoma of B-cells arising in a child with primary immunodeficiency disease. 282 Feb 54
The specific activities of
adenosine deaminase
(
ADA
) in 16 murine
tumor
cell lines derived from seven UV light-induced neoplasms (melanoma and fibrosarcoma) were determined. In each case, the specific activity of
ADA
correlated positively with the antigenicity of the
tumor
cells. Highly antigenic cell lines that regress upon introduction into syngeneic hosts had on average 4- to 6-fold higher
ADA
specific activities than cell lines of low antigenicity that grow progressively in syngeneic hosts. The antigenic differences are probably not related to intracellular cAMP levels, as the level of cAMP differed only 2-fold between the two groups of cell lines.
...
PMID:Antigenicity of UV radiation-induced murine tumors correlates positively with the level of adenosine deaminase activity. 282 50
The in vitro effect of short-term culture as well as the effect of retinol (ROH), retinoic acid (RA), muramyl dipeptide [( Abu']MDP), lipopolysaccharide (LPS), and gamma interferon (IFN-gamma) on the induction of the purine metabolic enzymes,
adenosine deaminase
(
ADA
), purine nucleoside phosphorylase (PNP), and 5'nucleotidase (5NT) in human peripheral blood monocytes (HPBM) was examined. HPBM isolated by centrifugal elutriation were cultured for up to 96 h. Following an initial time lag of 24 h, mean
ADA
activity from seven separate experiments as measured in nmoles/10(6) cells/h increased from a baseline of 31.3 +/- 9.3 to 57.8 +/- 16.4 (P less than 0.005) at 72 h and to 72 +/- 21.5 (P less than .025) by 96 h. 5NT activity increased from a baseline of 2.2 +/- 0.9 to a maximum of 44 +/- 10.1 by 72 h and then declined to 29 +/- 18 (P less than 0.005) by 96 h, while no significant change in PNP activity was observed. HPBM incubated for 3 d with optimal concentrations of LPS, RA, and IFN-gamma had increases in
ADA
and 5NT activity ranging from three- to 10-fold compared to HPBM cultured in media alone, whereas no effect was observed with ROH and [Abu']MDP. RA, but not ROH, significantly enhanced
ADA
activity in a monocytic leukemia cell (THP-1) line. Addition of RA or the
tumor
promoter, phorbol 12-myristic 13-acetate (PMA), to HPBM or THP-1 cells resulted in significant increases in 5NT activity with opposite effects on
ADA
activity. These findings suggest that the biological mechanisms associated with differentiation in normal and malignant monocytes seem to be related and that the sequence and degree to which the various differentiation agents induce the enzyme elevations are also related to the mechanisms of activation/differentiation.
...
PMID:Induction of adenosine deaminase and 5' nucleotidase activity in cultured human blood monocytes and monocytic leukemia (THP-1) cells by differentiating agents. 284 22
The level of
adenosine deaminase
(
ADA
) activity in mouse T-lymphocyte cultures was studied under different growth-supporting conditions and in mixed lymphocyte culture-derived long-term T-cell lines and clones. Early after the initiation of in vitro culture, the levels of
ADA
(2000 U/mg) were similar in bulk cultures either depleted or not depleted in Lyt-2+ T cells. Enrichment for cytolytic T lymphocytes (CTL) obtained by addition of exogenous interleukin 2 (IL-2), was accompanied by a net decrease of
ADA
activity (110 +/- 15 U/mg). All the tested CTL-A lines derived from such cultures were also characterized by a low or undetectable level of this enzyme (at best 160 +/- 70 U/mg) as previously observed. In contrast, "Lyt-2-" T-cell bulk cultures grown, without addition of exogenous IL-2, in the presence of gamma-irradiated H-2d stimulators maintained a constant level of
ADA
activity (1770 +/- 340 U/mg) for at least 3 months. Functionally distinct types of Lyt-2- T-cell lines were also analyzed: T-cell lines competent to activate B lymphocytes to growth and terminal maturation as well as others devoid of detectable functions showed a stable
ADA
level comparable to that expressed by the original bulk culture 1685 +/- 620 U/mg). The present results demonstrate that, like
tumor
cell lines, most normal T lymphocytes express a high level of
ADA
activity in culture, which strongly suggests that the low level of
ADA
activity exhibited by CTL is a characteristic of this functional subset.
...
PMID:Different functional subsets of cultured murine T cells express characteristic levels of adenosine deaminase activity. 293 Nov 83
The 5'-deoxy-5'-iodo-substituted analogs of adenosine and inosine are cytotoxic to
tumor
cells that have high activities of 5'-methylthioadenosine phosphorylase and purine nucleoside phosphorylase, respectively (Savarese, T.M., Chu, S-H., Chu, M.Y., and Parks, R. E., Jr. (1984) Biochem. Pharmacol. 34, 361-367). 5-Iodoribose 1-phosphate (5-IRib-1-P), the common intracellular metabolite of these 5'-iodonucleosides, has been synthesized enzymatically from 5'-deoxy-5'-iodoadenosine via
adenosine deaminase
from Aspergillus oryzae and human erythrocytic purine nucleoside phosphorylase. The purification and chemical properties of 5-IRib-1-P are described. The analog sugar phosphate inhibited purine nucleoside phosphorylase from human erythrocytes, phosphoglucomutase from rabbit muscle, and 5'-methylthioadenosine phosphorylase from Sarcoma 180 cells with Ki values of 26, 100, and 9 microM, respectively. Enzymes that react with 5-phosphoribosyl 1-pyrophosphate (P-Rib-PP), P-Rib-PP amidotransferase, hypoxanthine-guanine phosphoribosyltransferase, adenine phosphoribosyltransferase, and orotate phosphoribosyltransferase-orotidylate decarboxylase from extracts of Sarcoma 180 cells, were inhibited with Ki values of 49, 465, 307, and 275 microM, respectively. 5-IRib-1-P had no effect on P-Rib-PP synthetase. Since the Ki values of the analog sugar phosphate for 5'-methylthioadenosine phosphorylase and P-Rib-PP amidotransferase are much lower than the Km values of the natural substrates, Pi or P-Rib-PP which are reported to be present at nonsaturating concentrations under physiological conditions, these enzymes could be significantly inhibited by 5-IRib-1-P in intact cells.
...
PMID:5-Iodoribose 1-phosphate, an analog of ribose 1-phosphate. Enzymatic synthesis and kinetic studies with enzymes of purine, pyrimidine, and sugar phosphate metabolism. 293 89
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>